Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 1516374 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Ask a Question
Printer Friendly
PDF Brochure
Hard CopyAdd to Basket
Live Chat Live Help Software for Website

DNA Content Analysis and Invitro Cytotoxicity in Bladder Cancer Patients. Edition No. 1

VDM Publishing House, Nov 2010, Pages: 80


  Description  
   Authors   
    
    
    
     
  Enquire before Buying   
  Send to a Friend   

Transitional Cell Carcinoma accounts for more than 90% of bladder cancer. DNA analysis is the second most important application of flow cytometry. DNA content of individual cells give information about their ploidy in tumours and the distribution of cells across the cell cycle. Tumor DNA content has been found to be of prognostic importance for patients with many malignant tumors, such as carcinoma of urinary bladder. In-vitro cytotoxic studies on patients own cultured tumor tissue cells was done for the optimum cytotoxic combination of chemotherapeutic drugs and immunomodulators. This study was proposed investigate the DNA content evaluation and invitro monitoring of cytotoxicity produced by various chemotherapeutic agents viz Doxorubicin, Mitomycin C and Cisplatin on cultured cancer cells of patients having superficial TCC, individually as well as in combination of immunomodulating agents BCG and interferon alpha- 2b.Out of 25 samples nine were were aneuploid, one diploid and one tetraploid.Grade II samples were 70%. Out of 22 samples on which cytotoxicity test performed, 36.4% showed maximum cytotoxicity to the combination therapy and 5 showed to BCG drug.



For enquiries please call us on:
  +353-1-415-1241 (GMT Office Hours)
  1-917-300-0470 (EST Office Hours)

   All rights reserved. © Copyright 2012 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network


Research and Markets RSS Feeds